Muheem A, Shakeel F, Jahangir MA, et al
Am J Cardiol 2014;114:384-8.ArticlePubMed 123
Important safety considerations include the risk of pancreatitis (seek urgent medical attention for severe, persistent abdominal pain), gallbladder disease, and dehydration or acute kidney injury from severe gastrointestinal symptoms
Why the Change Is Happening Now The FDA announced that shortages of GLP-1s and tirzepatide are resolved as of April 2025, impacting compounded versionscustom-made options from pharmacies
We often recommend electrolyte supplementation as part of our GLP-1 management protocols. While these medications offer tremendous benefits for weight management and diabetes control, there are times when you might need to reconsider continued use: At Klarity Health, we work closely with patients to determine whether symptoms warrant a medication pause, dose adjustment, or different management strategy, notes Dr
Participants randomized to the placebo group received sham subcutaneous injections